$130 million CRC for biomarker translation opened at La Trobe

Circadian moves from 'biotech incubator' to drug development company

Two major pre-clinical breakthroughs have set Apollo Life Sciences on the road to commercialising the company's large molecule delivery systems, with orally delivered insulin and TNF blockers just two of its targets.

Gene silencing by small interfering RNAs (siRNAs) has emerged as an extremely useful technology for discovery biology, but off-target activity has proved a stumbling block. Detailed mechanistic insights and chemical modification of siRNAs can now improve the robustness of RNAi experiments, as Kate McDonald reports.

A new technology combining imaging with conventional flow cytometry has arrived in Australia. Kate McDonald spoke to the inventor, Amnis Corporation's Dr David Basiji.

The 11th International Congress on Human Genetics has secured a world-class line-up, not the least of whom is Elizabeth Blackburn. She's looking forward to returning to her former home to reveal more about the activity of her pet subject, telomerase.

The year 2006 will be a good one for biotech, according to San Francisco's bullish biotech maven, Steve Burrill.

Assoc Prof Shaun Jackson, from the Australian Centre for Blood Diseases at Monash University, has won this year's Amgen Medical Research Award for the discovery and development of a new treatment for coronary heart disease and stroke.

This week's federal budget contained a taxation measure designed to prime a 'brain siphon' that could help Australian biotechnology companies recruit experienced CEOs and other experienced senior executives from the US, Britain and Europe.

Sydney peptide therapeutics developer Peptech (ASX:PTD) has taken delivery of its hot new anti-inflammatory domain antibody (dAb) from UK ally Domantis, and plans to begin human clinical trials in 2007.

A new environment for pharmaceutical companies is on the horizon and it will be the fittest who survive, predicts Ian Nisbet.